Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit
Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Frontline Ibrutinib May Be Effective and Well Tolerated in Low-Risk MCL
Findings from this study demonstrated effectiveness with frontline ibrutinib in patients with previously treated, low-risk mantle cell lymphoma regardless of whether rituximab was added.
Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL
Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.
Revumenib Receives Priority Review From the FDA for Acute Leukemia Subset
The new drug application for revumenib is supported by data from the AUGMENT-101 trial of patients with KMT2A-rearranged acute myeloid leukemia or acute lymphoblastic leukemia.
Ibrutinib Plus Venetoclax Provides Survival Benefit in CLL
Progression-free and overall survival benefits were obtained with MRD-guided ibrutinib plus venetoclax when compared with fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.
Cadonilimab Plus Chemo Provides Survival Benefit in Gastric/GEJ Cancer
Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer
Frontline Durvalumab Regimen Improves PFS, Responses in Advanced Endometrial Cancer
